Microfluidic Protein Imaging Platform: Study of Tau Protein Aggregation and Alzheimer's Drug Response

Area of Science:

• Biochemistry
• Neuroscience
• Microfluidics

Background:

• Tau protein aggregation is a critical factor in Alzheimer's disease (AD) pathogenesis.
• Developing efficient methods for studying tau aggregation and evaluating AD drugs is essential.

Purpose of the Study:

• To develop and validate a microfluidic platform for on-chip imaging of tau protein aggregation and drug interactions.
• To assess the efficacy of methylthioninium chloride (MTC) in a cell-free system.
• To demonstrate the potential of microfluidic assays for rapid Alzheimer's disease drug evaluation.

Main Methods:

• Utilized a spiral-shaped passive micromixer for on-chip confocal imaging of tau aggregation.
• Performed numerical simulations and experiments to validate the micromixer design.
• Employed molecular modeling for adenosine triphosphate (ATP)-induced tau aggregation and an immunofluorescence antibody assay for tau restoration.
• Monitored drug dose-response using methylthioninium chloride (MTC) on-chip.

Main Results:

• Successfully validated the micromixer's performance for tau imaging and drug interaction studies.
• Demonstrated helical tau filament formation via molecular modeling.
• Quantified the dose-response of MTC, identifying optimal drug concentrations.
• Achieved reliable and repeatable on-chip tau imaging with significantly reduced sample volume and assay time (<2 hours).

Conclusions:

• Intensity-based tau imaging on microfluidic platforms can effectively study Alzheimer's drug responses.
• Cell-free, microfluidic tau protein assays are promising tools for on-chip drug evaluation in Alzheimer's disease research.